Profound Medical Corp
TSX:PRN
US |
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
|
US |
Estee Lauder Companies Inc
NYSE:EL
|
Consumer products
|
|
US |
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
|
US |
Church & Dwight Co Inc
NYSE:CHD
|
Consumer products
|
|
US |
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
|
US |
American Express Co
NYSE:AXP
|
Financial Services
|
|
US |
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
|
US |
Visa Inc
NYSE:V
|
Technology
|
|
CN |
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
|
US |
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
|
US |
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
|
US |
Coca-Cola Co
NYSE:KO
|
Beverages
|
|
US |
Target Corp
NYSE:TGT
|
Retail
|
|
US |
Walt Disney Co
NYSE:DIS
|
Media
|
|
US |
Mueller Industries Inc
NYSE:MLI
|
Machinery
|
|
US |
PayPal Holdings Inc
NASDAQ:PYPL
|
Technology
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
9.68
15.4
|
Price Target |
|
We'll email you a reminder when the closing price reaches CAD.
Choose the stock you wish to monitor with a price alert.
Johnson & Johnson
NYSE:JNJ
|
US | |
Estee Lauder Companies Inc
NYSE:EL
|
US | |
Exxon Mobil Corp
NYSE:XOM
|
US | |
Church & Dwight Co Inc
NYSE:CHD
|
US | |
Pfizer Inc
NYSE:PFE
|
US | |
American Express Co
NYSE:AXP
|
US | |
Nike Inc
NYSE:NKE
|
US | |
Visa Inc
NYSE:V
|
US | |
Alibaba Group Holding Ltd
NYSE:BABA
|
CN | |
3M Co
NYSE:MMM
|
US | |
JPMorgan Chase & Co
NYSE:JPM
|
US | |
Coca-Cola Co
NYSE:KO
|
US | |
Target Corp
NYSE:TGT
|
US | |
Walt Disney Co
NYSE:DIS
|
US | |
Mueller Industries Inc
NYSE:MLI
|
US | |
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one PRN stock under the Base Case scenario is 6.2 CAD. Compared to the current market price of 11.32 CAD, Profound Medical Corp is Overvalued by 45%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
Profound Medical Corp
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for PRN cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
Profound Medical Corp
Balance Sheet Decomposition
Profound Medical Corp
Current Assets | 48.5m |
Cash & Short-Term Investments | 34.1m |
Receivables | 7.2m |
Other Current Assets | 7.2m |
Non-Current Assets | 1.5m |
PP&E | 1.2m |
Intangibles | 374k |
Current Liabilities | 5.6m |
Accounts Payable | 2.7m |
Other Current Liabilities | 3m |
Non-Current Liabilities | 5.2m |
Long-Term Debt | 4.4m |
Other Non-Current Liabilities | 794k |
Earnings Waterfall
Profound Medical Corp
Revenue
|
7.9m
USD
|
Cost of Revenue
|
-3.1m
USD
|
Gross Profit
|
4.8m
USD
|
Operating Expenses
|
-35.5m
USD
|
Operating Income
|
-30.7m
USD
|
Other Expenses
|
3.1m
USD
|
Net Income
|
-27.6m
USD
|
Free Cash Flow Analysis
Profound Medical Corp
USD | |
Free Cash Flow | USD |
PRN Profitability Score
Profitability Due Diligence
Profound Medical Corp's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
Score
Profound Medical Corp's profitability score is 23/100. The higher the profitability score, the more profitable the company is.
PRN Solvency Score
Solvency Due Diligence
Profound Medical Corp's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Score
Profound Medical Corp's solvency score is 75/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PRN Price Targets Summary
Profound Medical Corp
According to Wall Street analysts, the average 1-year price target for PRN is 16.38 CAD with a low forecast of 14.26 CAD and a high forecast of 18.9 CAD.
Dividends
Current shareholder yield for PRN is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Profile
Country
Industry
Market Cap
Dividend Yield
Description
Profound Medical Corp. develops, manufactures and markets therapeutic platforms that combine real-time magnetic resonance imaging with directional and focused ultrasound technology for incision-free ablation of diseased tissue. The company is headquartered in Mississauga, Ontario and currently employs 146 full-time employees. The company went IPO on 2014-09-24. The firm is commercializing TULSA-PRO, which is a technology that combines real-time magnetic resonance imaging (MRI), transurethral ultrasound and closed-loop temperature feedback control. TULSA-PRO is designed to provide customizable and predictable radiation-free ablation of a surgeon-defined prostate volume while protecting the urethra and rectum to help preserve the patient’s natural functional abilities. The firm is also commercializing Sonalleve, which is a therapeutic platform for the treatment of uterine fibroids and palliative pain treatment of bone metastases.
Contact
IPO
Employees
Officers
The intrinsic value of one PRN stock under the Base Case scenario is 6.2 CAD.
Compared to the current market price of 11.32 CAD, Profound Medical Corp is Overvalued by 45%.